Historical Valuation
Ensysce Biosciences Inc (ENSC) is now in the Fair zone, suggesting that its current forward PS ratio of 6.83 is considered Fairly compared with the five-year average of -2.20. The fair price of Ensysce Biosciences Inc (ENSC) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.06
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Ensysce Biosciences Inc (ENSC) has a current Price-to-Book (P/B) ratio of 2.48. Compared to its 3-year average P/B ratio of 2.45 , the current P/B ratio is approximately 1.48% higher. Relative to its 5-year average P/B ratio of -10105.13, the current P/B ratio is about -100.02% higher. Ensysce Biosciences Inc (ENSC) has a Forward Free Cash Flow (FCF) yield of approximately -209.94%. Compared to its 3-year average FCF yield of -244.03%, the current FCF yield is approximately -13.97% lower. Relative to its 5-year average FCF yield of -172.28% , the current FCF yield is about 21.86% lower.
P/B
Median3y
2.45
Median5y
-10105.13
FCF Yield
Median3y
-244.03
Median5y
-172.28
Competitors Valuation Multiple
AI Analysis for ENSC
The average P/S ratio for ENSC competitors is 1.61, providing a benchmark for relative valuation. Ensysce Biosciences Inc Corp (ENSC.O) exhibits a P/S ratio of 6.83, which is 324.04% above the industry average. Given its robust revenue growth of -85.58%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ENSC
1Y
3Y
5Y
Market capitalization of ENSC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ENSC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ENSC currently overvalued or undervalued?
Ensysce Biosciences Inc (ENSC) is now in the Fair zone, suggesting that its current forward PS ratio of 6.83 is considered Fairly compared with the five-year average of -2.20. The fair price of Ensysce Biosciences Inc (ENSC) is between to according to relative valuation methord.
What is Ensysce Biosciences Inc (ENSC) fair value?
ENSC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ensysce Biosciences Inc (ENSC) is between to according to relative valuation methord.
How does ENSC's valuation metrics compare to the industry average?
The average P/S ratio for ENSC's competitors is 1.61, providing a benchmark for relative valuation. Ensysce Biosciences Inc Corp (ENSC) exhibits a P/S ratio of 6.83, which is 324.04% above the industry average. Given its robust revenue growth of -85.58%, this premium appears unsustainable.
What is the current P/B ratio for Ensysce Biosciences Inc (ENSC) as of Jan 10 2026?
As of Jan 10 2026, Ensysce Biosciences Inc (ENSC) has a P/B ratio of 2.48. This indicates that the market values ENSC at 2.48 times its book value.
What is the current FCF Yield for Ensysce Biosciences Inc (ENSC) as of Jan 10 2026?
As of Jan 10 2026, Ensysce Biosciences Inc (ENSC) has a FCF Yield of -209.94%. This means that for every dollar of Ensysce Biosciences Inc’s market capitalization, the company generates -209.94 cents in free cash flow.
What is the current Forward P/E ratio for Ensysce Biosciences Inc (ENSC) as of Jan 10 2026?
As of Jan 10 2026, Ensysce Biosciences Inc (ENSC) has a Forward P/E ratio of -0.32. This means the market is willing to pay $-0.32 for every dollar of Ensysce Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ensysce Biosciences Inc (ENSC) as of Jan 10 2026?
As of Jan 10 2026, Ensysce Biosciences Inc (ENSC) has a Forward P/S ratio of 6.83. This means the market is valuing ENSC at $6.83 for every dollar of expected revenue over the next 12 months.